Market disruption from Eli Lilly’s oral drug not to be underestimated
Max Stanyard, Healthcare and Life Sciences Senior Analyst at RSM UK, comments on Eli Lilly receiving FDA approval for its weight loss pill: “The launch of Eli Lilly’s first oral GPL-1 that can be taken any time of day, without food or water restrictions, is a remarkable arc of innovation.
“The company has been explicit: this drug comes at a lower price point in the US, and as a pill it carries none of the manufacturing bottlenecks that have constrained supply of similar injectable therapies.
“In the UK, obesity costs the NHS billions annually, yet obesity medication access remains rationed and patchy. If Foundayo's favourable economics translate into a competitive NICE submission, this could be the drug that finally makes meaningful population-level treatment a reality on the NHS – not just for the few, but for the many.
“The potential market disruption should not be underestimated. A pill-based obesity medication at accessible price points doesn't just expand the existing market – it fundamentally reshapes it. Pharmacy, primary care, digital health, and weight management services all need to be ready. The question for UK healthcare leaders and life sciences investors alike is not whether this will be disruptive – it's whether the UK will be fast enough to lead rather than follow.”